Medicare, Medicaid To Cover Wegovy For Consumers With Heart Disease

The Centers for Medicare and Medicaid Services (CMS) said the agency will cover Novo Nordisk’s Wegovy (semaglutide) when prescribed for Medicare beneficiaries with heart disease, if it is prescribed to reduce consumer risk of heart attacks and strokes. A CMS spokeperson said state Medicaid programs for low-income people and families would also be required to cover Wegovy when used to prevent heart disease for people with obesity.;

Wegovy was approved by the FDA as a treatment for weight loss for adults with obesity and for adults with overweight who have at least one weight-related comorbid condition . . .